approval

Crypto.com’s Dubai Entity Receives Full Operational Approval

Source Node:
Time Stamp: April 10, 2024 9:43 AM - Modified On: April 10, 2024 - Published By:
Source Cluster:
Republished By Plato

Crypto.com Exchange for Institutional Investors Launches as First Operational Milestone April 9, 2024, Dubai - Crypto.com, trusted by more than 80 million customers worldwide and the industry leader in regulatory compliance, security and privacy, announced today that its Dubai entity, CRO DAX Middle East FZE, has received full operational approval from Dubai’s Virtual Assets Regulatory Authority (VARA) and is launching the Crypto.com Exchange for institutional investors as its first operational milestone. This operational approval follows Crypto.com’s fulfillment of the pre-operational conditions stipulated in the Virtual Asset Service Provider Licence granted

Gome Fin Tech Announced Annual Results of 2023

Source Node:
Time Stamp: April 1, 2024 1:23 PM - Modified On: April 1, 2024 - Published By:
Source Cluster:
Republished By Plato

  Commercial Factoring Progresses Despite Stability Diversified Businesses Ready for Development HONG KONG, Mar 29, 2024 - (ACN Newswire) - Gome Finance Technology Co., Ltd.(Stock Code:628.HK,“Gome Fin Tech”or “the Company”,with its subsidiaries,the“Group”), announced its audited annual results for the year ended 31 December, 2023 (the “Reporting Period”). In 2023, the global geopolitical risks are frequent, the lack of economic recovery momentum and the widening trend of differentiation among countries are highlighted, and the risk spillover from European and US banks under the global high interest rate environment also casts a

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

Source Node:
Time Stamp: February 2, 2024 2:30 PM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

  New York, Feb 2, 2024 - (Plato Data)- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang. Avenue Therapeutics Finalizes Phase 3 Study for IV Tramadol with FDA Avenue Therapeutics, a subsidiary of Fortress Bio, has reached a significant milestone in its quest to introduce new therapies for neurologic diseases. The company

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

Source Node:
Time Stamp: January 29, 2024 6:55 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

New York, Jan. 29, 2024 - (Plato Data) - Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses. The data from the first eighteen participants who received the first six dose levels represented the readout, which was

Walking the Tightrope

Source Node:
Time Stamp: November 15, 2023 5:02 AM - Modified On: November 15, 2023 - Published By:
Source Cluster:
Republished By Plato

As we stand on the verge of a new era in crypto, it’s crucial to reaffirm the importance of decentralization. Beyond being a mere aspiration, decentralization serves as the lifeblood of the crypto world, standing as the pivotal force that draws the line between freedom and control. Amidst the hype surrounding the impending approval of a spot Bitcoin ETF in the United States, accompanied by the influx of capital from behemoths like BlackRock, the immediate market surge raises a serious question for the future of crypto. Are people here for

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:54 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:16 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Clockout Breaks New Ground in Wage Access. Launches and Expands its Reach to 42 States

Source Node:
Time Stamp: August 18, 2023 3:28 PM - Modified On: August 18, 2023 - Published By:
Source Cluster:
Republished By Plato

Historically, on-demand wage access required significant backend adjustments, coordination and often posed integration hurdles for employers. Clockout, a cutting-edge fintech platform, is pushing the boundaries of the traditional earned wage access model. In a bold move to address common industry challenges, the company has unveiled a streamlined, implementation-free model for employers, eliminating the need for cumbersome contracts and implementations and making offering their workforce immediate access to earned wages effortless. Clockout amplifies businesses' employee motivation, retention, and hiring leverage; while placing the power directly in the hands of the employees

Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings

Source Node:
Time Stamp: July 27, 2023 8:30 AM - Modified On: July 27, 2023 - Published By:
Source Cluster:
Republished By Plato

ORLANDO, FL / July 27, 2023 / Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its consumer sports recovery tape brand, Active Intelligence AI Tape (“AI Tape”), with products now available for purchase on Amazon and Activeintell.com. AI Tape is designed to combine many of the traditional benefits of kinesiology tape with the addition of soothing and therapeutic ingredients held in suspension with a proprietary adhesive mix. “We are very excited for the launch of our AI Tape brand, our first products targeting the consumer

Crypto’s Moment of Truth

Source Node:
Time Stamp: July 1, 2023 9:26 AM - Modified On: July 1, 2023 - Published By:
Source Cluster:
Republished By Plato

In a pivotal moment for crypto, recent news that BlackRock and others such as Fidelity have filed for spot Bitcoin ETFs propelled BTC to a yearly high of just under $31,700. What does the arrival of these significant players mean for the future of crypto? For years, the prospect of a Bitcoin ETF approval in the United States has been shrouded in uncertainty. However, the tides are turning this time, as the involvement of industry giants like BlackRock hints at a higher likelihood of approval. Deniz, our CEO, echoes this

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:21 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating